Based on the Globus Medical stock forecast from 10 analysts, the average analyst target price for Globus Medical is USD 93.17 over the next 12 months. Globus Medical’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Globus Medical is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Globus Medical’s stock price was USD 80.28. Globus Medical’s stock price has changed by -4.35% over the past week, -13.97% over the past month and +42.62% over the last year.
No recent analyst target price found for Globus Medical
No recent average analyst rating found for Globus Medical
Company Overview Globus Medical
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania. Read Less
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw a...Read More
Frequently Asked Questions About Globus Medical (GMED) Stock
Based on ratings from 10 analysts Globus Medical's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 15 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on GMED's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for GMED is USD 93.17 over the next 12 months. The maximum analyst target price is USD 115 while the minimum anlayst target price is USD 77.
GMED stock's Price/Earning ratio is 135.37.
Our analysis grades GMED stock's Price / Earning ratio at F. This means that GMED stock's Price/Earning ratio is above 70% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this GMED may be a overvalued for its sector.
The last closing price of GMED's stock was USD 80.28.
The most recent market capitalization for GMED is USD 11.43B.
Based on targets from 10 analysts, the average taret price for GMED is projected at USD 93.17 over the next 12 months.
This means that GMED's stock price may go up by +16.05% over the next 12 months.
We can't find any ETFs which contains Globus Medical's stock.
As per our most recent records Globus Medical has 5,000 Employees.
Globus Medical's registered address is 2560 General Armistead Avenue, Audubon, PA, United States, 19403.
You can get more information about it from Globus Medical's website at https://www.globusmedical.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Globus Medical (GMED) Stock
Based on ratings from 10 analysts Globus Medical's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 15 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on GMED's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for GMED is USD 93.17 over the next 12 months. The maximum analyst target price is USD 115 while the minimum anlayst target price is USD 77.
GMED stock's Price/Earning ratio is 135.37.
Our analysis grades GMED stock's Price / Earning ratio at F. This means that GMED stock's Price/Earning ratio is above 70% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this GMED may be a overvalued for its sector.
The last closing price of GMED's stock was USD 80.28.
The most recent market capitalization for GMED is USD 11.43B.
Based on targets from 10 analysts, the average taret price for GMED is projected at USD 93.17 over the next 12 months.
This means that GMED's stock price may go up by +16.05% over the next 12 months.
We can't find any ETFs which contains Globus Medical's stock.
As per our most recent records Globus Medical has 5,000 Employees.
Globus Medical's registered address is 2560 General Armistead Avenue, Audubon, PA, United States, 19403.
You can get more information about it from Globus Medical's website at https://www.globusmedical.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GMED !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
